The findings of a new clinical trial at UT Southwestern Medical Centre reveal that a commonly-prescribed weight-loss drug called liraglutide successfully targets fat that can endanger heart health. In adults who are overweight or have obesity combined with high cardiovascular risk, once-daily liraglutide combined with lifestyle interventions significantly lowered two types of fat that have been associated with the risk to heart health: visceral fat and ectopic fat. Visceral fat is stored within

GLP1 - Mechanism of Action